Log In
Print this Print this

Telomelysin (OBP-301)

  Manage Alerts
Collapse Summary General Information
Company Oncolys BioPharma Inc.
DescriptionOncolytic adenovirus
Molecular Target
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationLiver cancer
Indication DetailsTreat locally advanced hepatocellular carcinoma (HCC)
Regulatory Designation
Partner Medigen Biotechnology Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today